MX2014003153A - Prediccion de riesgo de evento cardiovascular y usos del mismo. - Google Patents
Prediccion de riesgo de evento cardiovascular y usos del mismo.Info
- Publication number
- MX2014003153A MX2014003153A MX2014003153A MX2014003153A MX2014003153A MX 2014003153 A MX2014003153 A MX 2014003153A MX 2014003153 A MX2014003153 A MX 2014003153A MX 2014003153 A MX2014003153 A MX 2014003153A MX 2014003153 A MX2014003153 A MX 2014003153A
- Authority
- MX
- Mexico
- Prior art keywords
- biomarkers
- event
- years
- cardiovascular risk
- risk event
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Abstract
Se describen biomarcadores, métodos, dispositivos, reactivos, sistemas y kits para la evaluación de riesgo de un evento cardiovascular (CV) dentro de 5 años. Los biomarcadores que pueden ser utilizados solos o en diversas combinaciones para evaluar el riesgo de un evento CV dentro de 5 años. Los métodos se proporcionan para evaluar el riesgo de un evento CV dentro de 5 años en un individuo, en donde los métodos incluyen detectar, en una muestra biológica de un individuo, por lo menos un valor de biomarcador, el biomarcador se selecciona de un grupo de biomarcadores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161541828P | 2011-09-30 | 2011-09-30 | |
PCT/US2012/058060 WO2013049674A1 (en) | 2011-09-30 | 2012-09-28 | Cardiovascular risk event prediction and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014003153A true MX2014003153A (es) | 2014-04-30 |
Family
ID=47993164
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014003153A MX2014003153A (es) | 2011-09-30 | 2012-09-28 | Prediccion de riesgo de evento cardiovascular y usos del mismo. |
MX2020004617A MX2020004617A (es) | 2011-09-30 | 2014-03-14 | Prediccion de riesgo de evento cardiovascular y usos del mismo. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020004617A MX2020004617A (es) | 2011-09-30 | 2014-03-14 | Prediccion de riesgo de evento cardiovascular y usos del mismo. |
Country Status (17)
Country | Link |
---|---|
US (3) | US20130085079A1 (es) |
EP (1) | EP2761289B1 (es) |
JP (3) | JP6652781B2 (es) |
KR (2) | KR102111624B1 (es) |
CN (4) | CN103959060B (es) |
AU (1) | AU2013202112B9 (es) |
BR (2) | BR122019023720B1 (es) |
CA (2) | CA3074279C (es) |
ES (1) | ES2777002T3 (es) |
HK (1) | HK1247666A1 (es) |
IL (1) | IL231387A (es) |
IN (1) | IN2014CN01970A (es) |
MX (2) | MX2014003153A (es) |
RU (1) | RU2651708C2 (es) |
SG (3) | SG10201607331WA (es) |
WO (1) | WO2013049674A1 (es) |
ZA (1) | ZA201401778B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10359425B2 (en) | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
JP6055966B2 (ja) * | 2010-06-07 | 2017-01-11 | マイクロ‐シグネチャー リミテッド | 検出方法 |
US20130116150A1 (en) | 2010-07-09 | 2013-05-09 | Somalogic, Inc. | Lung Cancer Biomarkers and Uses Thereof |
SG2014007454A (en) | 2010-08-13 | 2014-07-30 | Somalogic Inc | Pancreatic cancer biomarkers and uses thereof |
AU2012225273B2 (en) | 2011-03-10 | 2016-10-13 | Somalogic, Inc. | Aptamers for Clostridium difficile diagnostics |
MX2014003153A (es) * | 2011-09-30 | 2014-04-30 | Somalogic Inc | Prediccion de riesgo de evento cardiovascular y usos del mismo. |
JP6198047B2 (ja) * | 2013-08-02 | 2017-09-20 | 国立大学法人岐阜大学 | 冠動脈疾患の検査キット |
AU2014326975B2 (en) | 2013-09-24 | 2020-05-07 | Somalogic Operating Co., Inc. | Multiaptamer target detection |
WO2015140317A1 (en) * | 2014-03-21 | 2015-09-24 | Sanofi | New markers for the assessment of the risk for development of a cardiovascular disorder |
SG11201608566UA (en) * | 2014-06-05 | 2016-11-29 | Sanofi Aventis Deutschland | New markers for the assessment of an increased risk for mortality |
KR102328327B1 (ko) * | 2014-09-26 | 2021-11-22 | 소마로직, 인크. | 심혈관 위험 사건 예측 및 이의 용도 |
US11143659B2 (en) | 2015-01-27 | 2021-10-12 | Arterez, Inc. | Biomarkers of vascular disease |
CA2992139A1 (en) * | 2015-07-10 | 2017-01-19 | West Virginia University | Markers of stroke and stroke severity |
RU2602451C1 (ru) * | 2015-08-28 | 2016-11-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации | Способ диагностики генетической предрасположенности к развитию ишемического инсульта у больных с фибрилляцией предсердий |
CN116008563A (zh) * | 2016-02-08 | 2023-04-25 | 私募蛋白质体操作有限公司 | 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途 |
US20190071795A1 (en) * | 2016-03-09 | 2019-03-07 | Molecular Stethoscope, Inc. | Methods and systems for detecting tissue conditions |
CA3016107A1 (en) * | 2016-04-06 | 2017-10-12 | Nestec S.A. | Biomarkers for predicting degree of weight loss |
US20190159722A1 (en) | 2016-04-15 | 2019-05-30 | Omron Corporation | Biological information analysis device, system, and program |
CN105907857A (zh) * | 2016-04-29 | 2016-08-31 | 天津脉络生物科技有限公司 | 一种用于动脉血栓的分子标记物和试剂及其应用 |
WO2017214684A1 (en) * | 2016-06-17 | 2017-12-21 | Adelaide Research & Innovation Pty Ltd | Methods and products for identifying conditions associated with cardiac fibrotic remodelling |
EP3279665B1 (en) * | 2016-08-04 | 2020-07-08 | Roche Diagniostics GmbH | Circulating esm-1 (endocan) in the assessment of atrial fibrillation |
US11079394B2 (en) * | 2017-07-25 | 2021-08-03 | Vanderbilt University | Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure |
CN111480081A (zh) * | 2017-12-13 | 2020-07-31 | 豪夫迈·罗氏有限公司 | 用于预测脑卒中的循环血管生成素-2(Ang-2)和胰岛素样生长因子结合蛋白7(IGFBP7) |
RU2685859C1 (ru) * | 2018-07-04 | 2019-04-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ прогнозирования риска развития ишемического инсульта |
CN109192250B (zh) * | 2018-08-01 | 2021-12-07 | 华东理工大学 | 一种多相催化中克服表面物种快速迁移的加速模拟方法 |
US20210327540A1 (en) * | 2018-08-17 | 2021-10-21 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Use of machine learning models for prediction of clinical outcomes |
KR20210047304A (ko) * | 2018-08-22 | 2021-04-29 | 에프. 호프만-라 로슈 아게 | 심방 세동 평가에서 순환 spon-1 (스폰딘-1) |
BR112021008262A2 (pt) * | 2018-10-31 | 2021-10-26 | Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) | Biomarcadores de aterosclerose subclínica |
KR102125053B1 (ko) * | 2018-12-14 | 2020-06-19 | 가톨릭대학교 산학협력단 | 심혈관계 질환의 검출용 조성물 및 이를 포함하는 키트 |
MX2021009726A (es) | 2019-02-14 | 2021-09-14 | Mirvie Inc | Metodos y sistemas para determinar un estado relacionado con el embarazo de un sujeto. |
US11030743B2 (en) * | 2019-05-16 | 2021-06-08 | Tencent America LLC | System and method for coronary calcium deposits detection and labeling |
US10902955B1 (en) * | 2020-05-01 | 2021-01-26 | Georgetown University | Detecting COVID-19 using surrogates |
US20230393146A1 (en) * | 2020-10-20 | 2023-12-07 | Somalogic Operating Co., Inc. | Cardiovascular Event Risk Prediction |
RU2750716C1 (ru) * | 2020-11-23 | 2021-07-01 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) | Способ прогнозирования сердечно-сосудистых осложнений у больных низкого или умеренного сердечно-сосудистого риска путем оценки их психологического статуса |
WO2022165393A1 (en) * | 2021-02-01 | 2022-08-04 | Medtronic, Inc. | A method to identify lvad patients with elevated levels of blood activation using coupon tests |
RU2757752C1 (ru) * | 2021-04-26 | 2021-10-21 | Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) | Способ определения индивидуального профиля факторов суммарного сердечно-сосудистого риска у пациента трудоспособного возраста |
WO2023023748A1 (en) * | 2021-08-26 | 2023-03-02 | 3P Healthcare Pty Ltd | System and method for cardiovascular health assessment and risk management |
EP4230233A1 (en) * | 2022-02-22 | 2023-08-23 | mimiX Biotherapeutics Sàrl | Method for producing tissue constructs |
WO2023201054A1 (en) * | 2022-04-15 | 2023-10-19 | Memorial Sloan-Kettering Cancer Center | Multi-modal machine learning to determine risk stratification |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5660985A (en) * | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US20030144476A1 (en) * | 2000-03-06 | 2003-07-31 | Pankaj Agarwal | Novel compounds |
US20030224501A1 (en) * | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
US6930085B2 (en) * | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
CN102533972B (zh) * | 2002-05-09 | 2014-07-02 | 布赖汉姆妇女医院 | 作为心血管病的标志和治疗靶的1l1rl-1 |
JP2007516693A (ja) * | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
US20050181451A1 (en) * | 2004-02-12 | 2005-08-18 | Bates Harold M. | Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants |
CA2589277A1 (en) * | 2004-12-10 | 2006-06-15 | University Of Maryland, Baltimore | Serum amyloid a protein in inflammation and obesity |
CN2783324Y (zh) * | 2005-04-28 | 2006-05-24 | 穆海东 | 心血管疾病诊断和预测多指标蛋白芯片检测试剂盒 |
US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
AU2007210643B2 (en) * | 2006-01-31 | 2013-09-19 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method for determination of condition of disseminated intravascular coagulation syndrome |
EP2924440A3 (en) * | 2006-06-07 | 2016-03-09 | Health Diagnostic Laboratory, Inc. | Markers associated with arteriovascular events and methods of use thereof |
EP1887361A1 (en) * | 2006-08-07 | 2008-02-13 | Bio-Rad Pasteur | Method for the prediction of vascular events |
US7947447B2 (en) * | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
RU2376372C2 (ru) * | 2007-04-03 | 2009-12-20 | Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук | Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям |
EP2019318A1 (en) * | 2007-07-27 | 2009-01-28 | Erasmus University Medical Center Rotterdam | Protein markers for cardiovascular events |
EP2537529B1 (en) * | 2007-08-02 | 2018-10-17 | Gilead Biologics, Inc. | Loxl2 inhibitory antibodies and uses thereof |
GB0717637D0 (en) * | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
WO2009075566A1 (en) * | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
WO2009091581A2 (en) * | 2008-01-18 | 2009-07-23 | Vatrix Medical, Inc. | Diagnostic biomarkers for vascular aneurysm |
US8030097B2 (en) * | 2008-04-30 | 2011-10-04 | Versitech Limited and R & C Biogenius Limited | Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks |
CN102186483A (zh) * | 2008-08-11 | 2011-09-14 | 德克萨斯大学系统董事会 | 促进血管完整性的微rna及其用途 |
CN107085114B (zh) * | 2008-10-07 | 2021-05-25 | B.R.A.H.M.S有限公司 | 用于预测初次不利事件的生物标志物 |
WO2010144358A1 (en) * | 2009-06-08 | 2010-12-16 | Singulex, Inc. | Highly sensitive biomarker panels |
PT2264183T (pt) * | 2009-06-09 | 2017-03-14 | Gendiag Exe Sl | Marcadores de risco para doença cardiovascular |
US9122777B2 (en) * | 2009-06-15 | 2015-09-01 | Cardiodx, Inc. | Method for determining coronary artery disease risk |
US9217747B2 (en) * | 2009-10-29 | 2015-12-22 | Health Diagnostic Laboratory, Inc. | Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes |
CN102762743A (zh) * | 2009-12-09 | 2012-10-31 | 阿维埃尔公司 | 用于心血管疾病的诊断和分类的生物标记物检验 |
EP2542266A4 (en) * | 2010-03-03 | 2013-10-23 | Somalogic Inc | 4-1BB-BINDING APTAMERS AND USE THEREOF IN THE TREATMENT OF DISEASES AND DISORDERS |
MX2014003153A (es) * | 2011-09-30 | 2014-04-30 | Somalogic Inc | Prediccion de riesgo de evento cardiovascular y usos del mismo. |
CA2901394A1 (en) * | 2012-03-19 | 2013-09-26 | The Brigham And Women's Hosptial, Inc. | Growth differentiation factor (gdf) for treatment of diastolic heart failure |
-
2012
- 2012-09-28 MX MX2014003153A patent/MX2014003153A/es active IP Right Grant
- 2012-09-28 EP EP12836076.5A patent/EP2761289B1/en active Active
- 2012-09-28 KR KR1020147011813A patent/KR102111624B1/ko active IP Right Grant
- 2012-09-28 CN CN201280058717.0A patent/CN103959060B/zh active Active
- 2012-09-28 BR BR122019023720-4A patent/BR122019023720B1/pt active IP Right Grant
- 2012-09-28 AU AU2013202112A patent/AU2013202112B9/en active Active
- 2012-09-28 KR KR1020207013434A patent/KR102248900B1/ko active IP Right Grant
- 2012-09-28 CN CN202210145010.9A patent/CN114518458A/zh active Pending
- 2012-09-28 SG SG10201607331WA patent/SG10201607331WA/en unknown
- 2012-09-28 SG SG11201400904SA patent/SG11201400904SA/en unknown
- 2012-09-28 WO PCT/US2012/058060 patent/WO2013049674A1/en active Application Filing
- 2012-09-28 CA CA3074279A patent/CA3074279C/en active Active
- 2012-09-28 BR BR112014007214-0A patent/BR112014007214B1/pt active IP Right Grant
- 2012-09-28 CN CN201710329039.1A patent/CN107102151A/zh active Pending
- 2012-09-28 SG SG10201906900QA patent/SG10201906900QA/en unknown
- 2012-09-28 CN CN201710064624.3A patent/CN107422126B/zh active Active
- 2012-09-28 ES ES12836076T patent/ES2777002T3/es active Active
- 2012-09-28 CA CA2847903A patent/CA2847903C/en active Active
- 2012-09-28 IN IN1970CHN2014 patent/IN2014CN01970A/en unknown
- 2012-09-28 RU RU2014110508A patent/RU2651708C2/ru active
- 2012-09-28 US US13/631,567 patent/US20130085079A1/en not_active Abandoned
- 2012-09-28 JP JP2014533428A patent/JP6652781B2/ja active Active
-
2013
- 2013-12-31 US US14/145,026 patent/US20150168423A1/en not_active Abandoned
-
2014
- 2014-03-06 IL IL231387A patent/IL231387A/en active IP Right Grant
- 2014-03-11 ZA ZA2014/01778A patent/ZA201401778B/en unknown
- 2014-03-14 MX MX2020004617A patent/MX2020004617A/es unknown
-
2018
- 2018-05-29 HK HK18107011.0A patent/HK1247666A1/zh unknown
- 2018-05-30 JP JP2018103211A patent/JP6546318B2/ja active Active
-
2019
- 2019-10-25 JP JP2019193933A patent/JP6917432B2/ja active Active
-
2020
- 2020-01-23 US US16/751,102 patent/US20200166523A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004617A (es) | Prediccion de riesgo de evento cardiovascular y usos del mismo. | |
MX2013001042A (es) | Biomarcadores de cancer pancreatico y usos de los mismos. | |
MX355416B (es) | Biomarcadores de cancer de pulmon y usos de los mismos. | |
WO2013075055A3 (en) | Kits and methods for assessing appendicitis | |
EA030186B9 (ru) | Способ проведения количественных анализов | |
MY170164A (en) | Aptamer-based multiplexed assays | |
WO2013052505A3 (en) | Methods and devices for assessing risk to a putative offspring of developing a condition | |
WO2014186761A3 (en) | Methods for determining responsiveness to an anti-cd47 agent | |
EP3029153A3 (en) | Mesothelioma biomarkers and uses thereof | |
WO2013188686A3 (en) | Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome | |
WO2015067969A3 (en) | Method, array and use thereof for determining pancreatic cancer | |
NZ605698A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
GB201014837D0 (en) | Biomarker signatures and uses thereof | |
WO2011137388A3 (en) | Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample | |
WO2015095862A3 (en) | Microrna biomarkers for ovarian cancer | |
MX2016001719A (es) | Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. | |
MX2015004419A (es) | Deteccion de analito y determinacion de concentracion de analito mediante uso de perlas magnetizables. | |
WO2011130647A3 (en) | Compositions and methods for characterizing a myopathy | |
WO2014151290A3 (en) | Assay for predictive biomarkers | |
EP3557259A3 (en) | Methods and arrays for use in the same | |
WO2012139051A3 (en) | Autoantibody biomarkers for iga nephropathy | |
WO2014160237A3 (en) | Methods of prognosing preeclampsia | |
NZ605561A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
MX2016015531A (es) | Ensayo de inflamacion oral. | |
WO2013043041A3 (en) | Methods and compositions for diagnosing familial hypercholesterolemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |